Abstract :

Acne vulgaris is a worldwide disease which is mostly found in teenagers. This has a crucial impact on their life’s quality, particularly when endocrine disorders have been implicated. Current consideration regarding antibiotic stewardship, failing with antibiotic utilization, and the improvement of antibiotic-resistant Propionibacterium acnes, there are many treatment alternatives for pimple therapy have been acknowledged. A following analysis investigates hormonal treatments for the therapy of acne vulgaris.

---

Keywords :

Acne, Consensus Recommendation, Treatment.

---

References :

1. H. Gold, H. Baldwin, and T. Lin, “Management of comedonal acne vulgaris with fixed‐combination topical therapy,” Journal of cosmetic dermatology, vol. 17, no. 2, pp. 227-231, 2018.
2. S. K. Fuchs, V. K. Ortner, F. S. Hansen, P. A. Philipsen, and M. Haedersdal, “Subclinical effects of adapalene‐benzoyl peroxide: a prospective in vivo imaging study on acne micromorphology and transfollicular delivery,” Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 6, pp. 1377-1385, 2021.
3. Z. Eichenfield, J. Sprague, and L. F. Eichenfield, “Management of Acne Vulgaris: A Review,” JAMA, vol. 326, no. 20, pp. 2055-2067, 2021.
4. Dréno et al., “Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison,” American journal of clinical dermatology, vol. 19, no. 2, pp. 275-286, 2018.
5. K. Emmerich, C. G. Purvis, and S. R. Feldman, “An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne,” Expert Opinion on Pharmacotherapy, no. just-accepted, 2021.
6. D. Callender, H. Baldwin, F. E. Cook-Bolden, A. F. Alexis, L. Stein Gold, and E. Guenin, “Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice,” American journal of clinical dermatology, pp. 1-13, 2021.
7. K. C. Leung, B. Barankin, J. M. Lam, K. F. Leong, and K. L. Hon, “Dermatology: how to manage acne vulgaris,” Drugs in context, vol. 10, 2021.
8. C. N. Kaminska, “Treatment of acne and acne-related scarring with fixed combination clindamycin phosphate and benzoyl peroxide gel (1.2%/3.75%) and tretinoin gel microsphere 0.06% in an Asian American transgender female,” SAGE Open Medical Case Reports, vol. 8, p. 2050313X20984038, 2020.
9. Latter, J. E. Grice, Y. Mohammed, M. S. Roberts, and H. A. E. Benson, “Targeted topical delivery of retinoids in the management of acne vulgaris: current formulations and novel delivery systems,” Pharmaceutics, vol. 11, no. 10, p. 490, 2019.
10. A. See, C. L. Goh, N. Hayashi, D. H. Suh, and F. A. Casintahan, “Optimizing the use of topical retinoids in Asian acne patients,” The Journal of dermatology, vol. 45, no. 5, pp. 522-528, 2018.
11. S. Kolli, D. Pecone, A. Pona, A. Cline, and S. R. Feldman, “Topical retinoids in acne vulgaris: a systematic review,” American journal of clinical dermatology, pp. 1-21, 2019.
12. Samadi et al., “Efficacy assessments of tretinoin-loaded nano lipid carriers in acne vulgaris: a double blind, split-face randomized clinical study,” Archives of Dermatological Research, pp. 1-9, 2021.
13. Dogra et al., “Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: a phase 3, randomized, double-blind study,” Journal of Dermatological Treatment, vol. 32, no. 8, pp. 925-933, 2021.
14. K. Tyring, L. H. Kircik, D. M. Pariser, E. Guenin, V. Bhatt, and R. Pillai, “Novel Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: Assessment of efficacy and safety in patients aged 9 years and older,” Journal of drugs in dermatology: JDD, vol. 17, no. 10, pp. 1084-1091, 2018.
15. F. Salem, R. M. Kharshoum, S. M. Awad, M. A. Mostafa, and H. A. Abou-Taleb, “Tailoring of retinyl palmitate-based ethosomal hydrogel as a novel nanoplatform for acne vulgaris management: Fabrication, optimization, and clinical evaluation employing a split-face comparative study,” International Journal of Nanomedicine, vol. 16, p. 4251, 2021.
16. Mazzarello et al., “Clinical assessment of new topical cream containing two essential oils combined with tretinoin in the treatment of acne,” Clinical, cosmetic and investigational dermatology, vol. 13, p. 233, 2020.
17. S. Barbieri, N. Spaccarelli, D. J. Margolis, and W. D. James, “Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments,” Journal of the American Academy of Dermatology, vol. 80, no. 2, pp. 538-549, 2019.
18. Dreno, E. Bagatin, U. Blume‐Peytavi, M. Rocha, and H. Gollnick, “Female type of adult acne: Physiological and psychological considerations and management,” JDDG: Journal Der Deutschen Dermatologischen Gesellschaft, vol. 16, no. 10, pp. 1185-1194, 2018.
19. W. Marson and H. E. Baldwin, “An overview of acne therapy, part 1: topical therapy, oral antibiotics, laser and light therapy, and dietary interventions,” Dermatologic clinics, vol. 37, no. 2, pp. 183-193, 2019.
20. Mwanthi and A. L. Zaenglein, “Update in the management of acne in adolescence,” Current opinion in pediatrics, vol. 30, no. 4, pp. 492-498, 2018.
21. Santer, N. A. Francis, D. Platt, E. A. Eady, and A. M. Layton, “Stemming the tide of antimicrobial resistance: implications for management of acne vulgaris,” vol. 68, ed: British Journal of General Practice, 2018, pp. 64-65.
22. S. Reddy, L. C. DeBord, R. Gupta, P. Kapadia, A. Mohanty, and H. Dao Jr, “Antibiotics for acne vulgaris: using instagram to seek insight into the patient perspective,” Journal of Dermatological Treatment, 2019.
23. K. Trivedi, S. S. Bosanac, R. K. Sivamani, and L. N. Larsen, “Emerging therapies for acne vulgaris,” American journal of clinical dermatology, vol. 19, no. 4, pp. 505-516, 2018.
24. Dursun, M. Daye, and K. Durmaz, “Acne and rosacea: What’s new for treatment?,” Dermatologic therapy, vol. 32, no. 5, p. e13020, 2019.
25. Deyno et al., “Essential oils as topical anti-infective agents: A systematic review and meta-analysis,” Complementary therapies in medicine, vol. 47, p. 102224, 2019.
26. Drake, S. Reyes-Hadsall, J. S. Barbieri, and A. Mostaghimi, “New Developments in Topical Acne Therapy,” American Journal of Clinical Dermatology, pp. 1-12, 2022.
27. Alshammari, “Efficacy of Generic vs. branded Isotretinoin for Acne treatment: a case report,” Journal of Advanced Pharmacy Education & Research| Jan-Mar, vol. 11, no. 1, 2021.
28. N. Olsufyeva and V. S. Yankovskaya, “Main trends in the design of semi-synthetic antibiotics of a new generation,” Russian Chemical Reviews, vol. 89, no. 3, p. 339, 2020.
29. A. Kayiran, A. S. Karadag, S. Al-Khuzaei, W. Chen, and L. C. Parish, “Antibiotic resistance in acne: mechanisms, complications and management,” American Journal of Clinical Dermatology, pp. 1-7, 2020.
30. Abdel Hay, R. Hegazy, M. Abdel Hady, and N. Saleh, “Clinical and dermoscopic evaluation of combined (salicylic acid 20% and azelaic acid 20%) versus trichloroacetic acid 25% chemical peel in acne: an RCT,” Journal of Dermatological Treatment, vol. 30, no. 6, pp. 572-577, 2019.
31. Szymańska, E. Budzisz, and A. Erkiert-Polguj, “Efficacy of 30% azelaic acid peel in the nonpharmacological treatment of facial acne,” Journal of Dermatological Treatment, vol. 32, no. 3, pp. 291-296, 2021.
32. Bisht et al., “Azelaic acid and Melaleuca alternifolia essential oil co-loaded vesicular carrier for combinational therapy of acne,” Therapeutic Delivery, no. 0, 2021.
33. Liang, D. Sun, Y. Yang, M. Li, H. Li, and L. Chen, “Discovery of metal-based complexes as promising antimicrobial agents,” European Journal of Medicinal Chemistry, vol. 224, p. 113696, 2021.
34. Khatoon et al., “A comprehensive Review on Buthūr Labaniyya (Acne vulgaris) with special references of Unani System of Medicine,” seed, vol. 28, p. 31, 2021.
35. Li et al., “The Prebiotic Effect of Triple Biotic Technology on Skin Health,” Journal of Cosmetics, Dermatological Sciences and Applications, vol. 11, no. 4, pp. 304-319, 2021.
36. Kameswararao, C. Sujani, N. V. N. Koteswararao, A. Rajarao, and P. N. S. Satyanarayanamma, “A Brief Review on Acne Vulgaris,” Research Journal of Pharmacology and Pharmacodynamics, vol. 11, no. 3, pp. 109-119, 2019.
37. Q. Del Rosso, L. Kircik, and E. Tanghetti, “Management of truncal acne vulgaris with topical dapsone 7.5% gel,” The Journal of clinical and aesthetic dermatology, vol. 11, no. 8, p. 45, 2018.
38. A. Temiz and M. Daye, “Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits?,” Cutaneous and Ocular Toxicology, no. just-accepted, pp. 1-17, 2021.
39. Jakhar, V. Kadian, and R. Rao, “Dapsone-Loaded Microsponge Gel for Acne Management: Preparation, Characterization and Anti-Microbial Activity,” Micro and Nanosystems, vol. 13, no. 2, pp. 211-222, 2021.
40. Y. Moore et al., “Once-daily Dapsone 7.5% Gel for the Treatment of Acne Vulgaris in Preadolescent Patients: A Phase IV, Open-label, 12-week Study,” The Journal of Clinical and Aesthetic Dermatology, vol. 14, no. 4, p. 43, 2021.
41. Bharti and H. C. Vadlamudi, “A strategic review on the involvement of receptors, transcription factors and hormones in acne pathogenesis,” Journal of Receptors and Signal Transduction, vol. 41, no. 2, pp. 105-116, 2021.
42. -X. Cong, D. Hao, X. Wen, X.-H. Li, G. He, and X. Jiang, “From pathogenesis of acne vulgaris to anti-acne agents,” Archives of dermatological research, vol. 311, no. 5, pp. 337-349, 2019.
43. W. Clayton, K. Göbel, C. M. Niessen, R. Paus, M. A. M. Van Steensel, and X. Lim, “Homeostasis of the sebaceous gland and mechanisms of acne pathogenesis,” British Journal of Dermatology, vol. 181, no. 4, pp. 677-690, 2019.
44. L. Kanwar, T. Haider, A. Kumari, S. Dubey, P. Jain, and V. Soni, “Models for acne: A comprehensive study,” Drug discoveries & therapeutics, vol. 12, no. 6, pp. 329-340, 2018.
45. Briganti, E. Flori, A. Mastrofrancesco, and M. Ottaviani, “Acne as an altered dermato‐endocrine response problem,” Experimental Dermatology, vol. 29, no. 9, pp. 833-839, 2020.
46. A. Rocha and E. Bagatin, “Adult-onset acne: prevalence, impact, and management challenges,” Clinical, cosmetic and investigational dermatology, vol. 11, p. 59, 2018.
47. Iftikhar and N. Choudhry, “Serum levels of androgens in acne & their role in acne severity,” Pakistan journal of medical sciences, vol. 35, no. 1, p. 146, 2019.
48. Bienenfeld, S. Azarchi, K. L. Sicco, S. Marchbein, J. Shapiro, and A. R. Nagler, “Androgens in women: Androgen-mediated skin disease and patient evaluation,” Journal of the American Academy of Dermatology, vol. 80, no. 6, pp. 1497-1506, 2019.
49. Kumtornrut, T. Yamauchi, S. Koike, S. Aiba, and K. Yamasaki, “Androgens modulate keratinocyte differentiation indirectly through enhancing growth factor production from dermal fibroblasts,” Journal of dermatological science, vol. 93, no. 3, pp. 150-158, 2019.
50. March and S. Witchel, “Acne, Hirsutism, and Other Signs of Increased Androgens,” in Endocrine Conditions in Pediatrics: Springer, 2021, pp. 85-94.
51. E. A. Common, J. N. Barker, and M. A. M. van Steensel, “What does acne genetics teach us about disease pathogenesis?,” British Journal of Dermatology, vol. 181, no. 4, pp. 665-676, 2019.
52. C. Zouboulis, A. Nogueira da Costa, S. Fimmel, and K. C. Zouboulis, “Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific,” Journal of the European Academy of Dermatology and Venereology, vol. 34, no. 7, pp. 1555-1563, 2020.
53. G. Clatici, C. Voicu, C. Voaides, A. Roseanu, M. Icriverzi, and S. Jurcoane, “Diseases of Civilization–Cancer, Diabetes, Obesity and Acne–the Implication of Milk, IGF-1 and mTORC1,” Mædica, vol. 13, no. 4, p. 273, 2018.
54. Wardhana, R. Vebryanti, G. A. Karmila, G. A. Praharsini, and R. S. Tallo, “Association between Psychological Stress and Insulin like Growth Factor-1 (IGF-1) with Acne Vulgaris,” 2021.
55. Aktaş Karabay, Z. A. Saltık, and Ö. Unay Demirel, “Evaluation of serum FoxO1, mTORC1, IGF‐1, IGFBP‐3 levels, and metabolic syndrome components in patients with acne vulgaris: A prospective case‐control study,” Dermatologic therapy, vol. 33, no. 6, p. e13887, 2020.
56. Rodighiero et al., “Do acne treatments affect insulin‐like growth factor‐1 serum levels? A clinical and laboratory study on patients with acne vulgaris,” Dermatologic therapy, vol. 33, no. 3, p. e13439, 2020.
57. Magri et al., “Multidisciplinary approach to prostatitis,” (in eng), Arch Ital Urol Androl, vol. 90, no. 4, pp. 227-248, Jan 18 2019, doi: 10.4081/aiua.2018.4.227.
58. Ebrahimi et al., “Association between CYP19A< G rs700518 Polymorphism with Acne Vulgaris and its severity: influence on sex hormones level,” International journal of molecular and cellular medicine, vol. 8, no. 2, p. 162, 2019.
59. Akdoğan, S. Doğan, N. Atakan, and B. Yalçın, “Association of serum hormone levels with acne vulgaris: Low estradiol level can be a pathogenetic factor in female acne,” Our Dermatology Online/Nasza Dermatologia Online, vol. 9, no. 3, 2018.
60. M. DeGrazia, R. Rolader, D. M. Thiboutot, and H. Yeung, “Eligibility criteria related to hormone therapy in acne clinical trials: a systematic review,” The Journal of Investigative Dermatology, no. 1, pp. 189-191, 2020.
61. E. Ashton et al., “Antiandrogen treatment in women with acne: a controlled trial,” in Antiandrogen-Estrogen Therapy for Signs of Androgenization: De Gruyter, 2019, pp. 117-130.
62. Singh, A. Chaudhary, M. M. P. Singh, M. P. S. Sawhney, B. Karunanand, and B. K. Anand, “A Study of Hormonal Profile (Luteinizing Hormone, Estrogen, Follicle Stimulating Hormone and Prolactin) In the Women Suffering From Acne Vulgaris,” Annals of International Medical and Dental Research, vol. 4, no. 4, p. 22, 2018.
63. -P. Wang et al., “An unusual case of ectopic corticotrophin-releasing hormone syndrome caused by an adrenal noncatecholamine-secreting pheochromocytoma: a case report,” BMC endocrine disorders, vol. 18, no. 1, pp. 1-5, 2018.
64. Bansal, K. Sardana, G. Vats, L. Sharma, U. C. Garga, and A. Khurana, “A prospective study examining trigger factors and hormonal abnormalities in adult female acne,” Indian Dermatology Online Journal, vol. 11, no. 4, p. 544, 2020.
65. Azanbayeva, G. Batpenova, T. Tarkina, T. Algazina, and T. Kotlyarova, “СLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH ADOLESCENCE ACNE AND ACNE TARDA,” Georgian medical news, no. 282, pp. 103-106, 2018.
66. Kelestimur and K. Unluhizarci, “Congenital Adrenal Hyperplasia (CAH): Definition and Enzymatic Defects in Various Forms,” in Fertility and Reproductive Outcomes in Different Forms of Congenital Adrenal Hyperplasia: Springer, 2021, pp. 1-18.
67. Chen, Y. Zheng, and Y. Liang, “Analysis of potential genes and pathways involved in the pathogenesis of acne by bioinformatics,” BioMed research international, vol. 2019, 2019.
68. Soleymani, M. H. Farzaei, A. Zargaran, S. Niknam, and R. Rahimi, “Promising plant-derived secondary metabolites for treatment of acne vulgaris: a mechanistic review,” Archives of dermatological research, vol. 312, no. 1, pp. 5-23, 2020.
69. Zhang et al., “Toll-like receptor 2 plays a critical role in pathogenesis of acne vulgaris,” Biomedical Dermatology, vol. 3, no. 1, pp. 1-6, 2019.
70. Zhang et al., “Serum levels of proinflammatory, anti-inflammatory cytokines, and RANKL/OPG in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome,” Modern rheumatology, vol. 29, no. 3, pp. 523-530, 2019.
71. Wang et al., “The anti-inflammatory activities of Propionibacterium acnes CAMP factor-targeted acne vaccines,” Journal of Investigative Dermatology, vol. 138, no. 11, pp. 2355-2364, 2018.
72. W. Agak et al., “Phenotype and antimicrobial activity of Th17 cells induced by Propionibacterium acnes strains associated with healthy and acne skin,” Journal of Investigative Dermatology, vol. 138, no. 2, pp. 316-324, 2018.
73. Rosette, F. J. Agan, A. Mazzetti, L. Moro, and M. Gerloni, “Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro,” Journal of drugs in dermatology: JDD, vol. 18, no. 5, pp. 412-418, 2019.
74. -y. He et al., “Association of brain-derived neurotrophic factor levels and depressive symptoms in young adults with acne vulgaris,” BMC psychiatry, vol. 19, no. 1, pp. 1-8, 2019.
75. Shan, F. Meng, C. Tang, L. Zhou, Z. Lu, and Y. Lu, “Surfactin-oleogel with therapeutic potential for inflammatory acne vulgaris induced by Propionibacterium acnes,” Applied microbiology and biotechnology, pp. 1-14, 2021.
76. C. Zouboulis et al., “Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa,” Dermatology, vol. 236, no. 1, pp. 25-30, 2020.
77. N. Clark, A. Whiting, and P. McCaffery, “Retinoic acid receptor-targeted drugs in neurodegenerative disease,” Expert Opinion on Drug Metabolism & Toxicology, vol. 16, no. 11, pp. 1097-1108, 2020.
78. Yavuz and M. Ozcimen, “An evaluation of peripapillar choroidal thickness in patients receiving systemic isotretinoin treatment,” Cutaneous and ocular toxicology, vol. 38, no. 1, pp. 25-28, 2019.
79. Ferreira, J. Napoli, T. Enver, L. Bernardino, and L. Ferreira, “Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine,” Nature Communications, vol. 11, no. 1, pp. 1-14, 2020.
80. Rao, S. C. Douglas, and J. M. Hall, “Endocrine Disrupting Chemicals, Hormone Receptors, and Acne Vulgaris: A Connecting Hypothesis,” Cells, vol. 10, no. 6, p. 1439, 2021.
81. Stefanovic, A. D. Irvine, and C. Flohr, “The Role of the Environment and Exposome in Atopic Dermatitis,” (in eng), Curr Treat Options Allergy, pp. 1-20, May 21 2021, doi: 10.1007/s40521-021-00289-9.
82. Passeron, J. Krutmann, M. L. Andersen, R. Katta, and C. C. Zouboulis, “Clinical and biological impact of the exposome on the skin,” Journal of the European Academy of Dermatology and Venereology, vol. 34, pp. 4-25, 2020.
83. Kaya Ozden and A. S. Karadag, “Could endocrine disruptors be a new player for acne pathogenesis? The effect of bisphenol A on the formation and severity of acne vulgaris: A prospective, case‐controlled study,” Journal of Cosmetic Dermatology, vol. 20, no. 11, pp. 3573-3579, 2021.
84. FitzPatrick, “Endocrine Disrupting Chemicals and Personal Care Products: Risk Awareness and Exposure Assessment for Women’s Reproductive Health,” 2021.
85. Dzimitrowicz et al., “Cold atmospheric pressure plasmas as versatile tools for effective degradation of a mixture of hazardous and endocrine disturbing compounds from liquid wastes,” Journal of Environmental Chemical Engineering, vol. 9, no. 6, p. 106718, 2021.